Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2024-11, Vol.190, p.S23-S24
Main Authors: Wu, Xiaohua, Xia, Lingfang, Zhang, Keqiang, Tang, Ying, Zhang, Guonan, Wang, Danbo, Lou, Hanmei, Liu, Naifu, Zhang, Hongping, Chen, Hongwei, Wang, Ke, Wei, Shuqing, Wang, Li, Gao, Kun, Li, Guiling, Zhang, Huifeng, Hu, Yuanjing, Zhou, Xianfeng, Wang, Yuting, Wang, Quanren
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0090-8258
DOI:10.1016/j.ygyno.2024.07.040